Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 976 to 1000 of 1141 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
166 increased signaling (GO:0023052) oxysterols receptor LXR-beta (PR:000011394) 167: Activation, LXR
165 increased kidney failure (MP:0003606) 759: Increased, Kidney Failure
164 increased signaling (GO:0023052) 5-hydroxytryptamine receptor 2C (PR:000001168) 9: Activation, 5HT2c
163 increased hepatocellular carcinoma (MESH:D006528)
162 increased hepatocyte proliferation (GO:0072574) 269: Induction, Sustained Cell Proliferation
161 increased hepatotoxicity (MI:2141) 270: Induction, Sustained Hepatotoxicity
160 decreased nitric-oxide synthase activity (GO:0004517) nitric oxide synthase, brain (PR:000011326) 147: Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
159 decreased Decreased liver function (HP:0001410) 164: Induction, Liver “Dysfunctional” Changes by CGA 330050
158 increased metabolic process (GO:0008152) metabolite (CHEBI:25212) 77: Production, Critical Metabolites (CGA 330050 and CGA 265307)
157 increased metabolic process (GO:0008152) thiamethoxam (CHEBI:39185) 77: Production, Critical Metabolites (CGA 330050 and CGA 265307)
156 occurrence Cyanosis (MESH:D003490) 321: N/A, Cyanosis occurs
155 decreased hemoglobin (CHEBI:35143) 173: N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
154 increased Methemoglobinemia (MESH:D008708) 173: N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
153 increased hemosiderosis (MESH:D006486) 161: Increase, Liver and splenic hemosiderosis
152 increased liver vascular congestion (MP:0010019) 246: Increase, RBC congestion in liver
151 increased erythrocyte (CL:0000232)
150 decreased gene expression (GO:0010467) glucose-6-phosphate 1-dehydrogenase (PR:000007749) 131: Down Regulation, Gulcose-6-phosphate dehydrogenase
149 increased hemoglobin binding (GO:0030492) 118: Formation, Formation of hemoglobin adducts
148 increased hemoglobin biosynthetic process (GO:0042541) xenobiotic (CHEBI:35703) 118: Formation, Formation of hemoglobin adducts
147 increased hemolysis (MESH:D006461) 250: Damaging, Red blood cells; hemolysis
146 abnormal gene expression (GO:0010467) hemoglobin subunit alpha (human) (PR:P69905) 21: Altered regulation, Alpha hemoglobin
145 increased heme oxidation (GO:0006788) 213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)
144 decreased estrogen receptor activity (GO:0030284) estrogen receptor (PR:000007204)
143 abnormal developmental process (GO:0032502) reproductive organ (UBERON:0003133) 364: Impaired development of, Reproductive organs
142 abnormal larval development (GO:0002164)